Baseline determinants of remission of type 2 diabetes in response to short‐term insulin‐based therapy: The pivotal role of beta‐cell function

This study identified the factors contributing to diabetes remission in response to short-term insulin-based therapy. Adult patients with type 2 diabetes of less than 7 years duration were randomly assigned to different treatment regimens for 8 weeks, followed by a 12-week washout period to evaluate remission. Beta-cell function was assessed using four measures. The results showed that 34.4% of participants achieved diabetes remission. Those who achieved remission had lower HbA1c levels and better beta-cell function at baseline. Higher baseline beta-cell function also predicted a longer time to glycaemic relapse after cessation of insulin therapy. The study suggests that beta-cell function is crucial in determining the likelihood of achieving diabetes remission with short-term insulin-based therapy.